跳至主要内容
临床试验/NCT05612958
NCT05612958已完成不适用

Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds: Single Center, Prospective, Comparative, Randomized, Double Blinded (Subject, Evaluator), Matched Pairs Design, Non-inferiority, Pivotal Clinical Trial

Dongkook Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2021年3月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
82
试验地点
1
主要终点
Change in WSRS(Wrinkle Severity Rating Scale) score by independent evaluators from Baseline to Week 24.

研究概览

简要总结

The purpose of the study is to assess the efficacy and safety of a 'Graft/prosthesis, biomaterial (DKM410)' in the treatment of both nasolabial folds.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 19 years and older
  • Wrinkle Severity Rating Scale (WSRS) 3 or 4
  • Visually symmetrical bilateral nasolabial folds
  • Agreed not to use any dermatological treatment and wrinkle-improving functional cosmetics.
  • Voluntarily decided to participate in the study and signed the informed consent form
  • Willing to follow the protocol

排除标准

  • History of undergoing a permanent or semi-permanent filler treatment on the face
  • Received soft tissue augmentation using HA filler or collagen for nasolabial folds within 18 months from screening.
  • Received any surgery or laser treatment, chemical filling, heart attack, or Botox injection within 24 weeks from the screening
  • History of allergic reactions to Hyaluronic Acid or Gram-positive bacteria protein
  • Hypersensitivity to Lidocaine or amide local anesthetic
  • Positive for the intradermal response test
  • History of severe or plurality of allergies
  • Having skin inflammation or infection in nasolabial folds
  • History of keloid formation, hyperpigmentation, or hypertrophic scars on the face.
  • History of streptococcal disease
  • Uncontrolled epilepsy
  • Having or being currently suffering from autoimmune diseases
  • History of immunodeficiency or immunosuppressive drugs
  • History of herpetic eruption
  • Having bleeding disorder or blood clotting disorder
  • Having anticoagulant drugs or components within 72 hours from the application of medical advice
  • Received antiplatelet drugs within 2 weeks from the application of medical advice
  • Having high dose vitamin E or nonsteroidal anti-inflammatory drugs (NSAIDs) and high dose vitamin C within one week from the application of medical advice
  • Received drugs that inhibit or decrease liver metabolism
  • Clinically significant abnormalities on electrocardiogram
  • Pregnant or breast-feeding or who planning to conceive
  • Clinically severe cardiovascular, digestive, respiratory, endocrine, central nervous system disorders or mental illness
  • Other investigational products or procedures within 3 months from screening
  • Not eligible due to other reasons at the investigator's discretion

结局指标

主要结局

Change in WSRS(Wrinkle Severity Rating Scale) score by independent evaluators from Baseline to Week 24.

时间窗: Baseline and Week 24

Independent evaluators evaluate the WSRS score change at Week 24 compared to baseline.

次要结局

  • Change in Wrinkle Severity Rating Scale(WSRS) score by independent evaluators from Baseline to Weeks 8, 16 and 48.(Baseline and Weeks 8, 16 and 48.)
  • Success rate of treatment(N%) by independent evaluators from Baseline to Weeks 8, 16, 24 and 48.(Baseline and Weeks 8, 16, 24 and 48.)
  • Change in Wrinkle Severity Rating Scale(WSRS) score by investigator from Baseline to Weeks 8, 16, 24 and 48.(Baseline and Weeks 8, 16, 24 and 48.)
  • Success rate of treatment(N%) by investigator from Baseline to Weeks 8, 16, 24 and 48.(Baseline and Weeks 8, 16, 24 and 48.)
  • Global Aesthetic Improvement Scale (GAIS) from Baseline to Weeks 8, 16, 24 and 48.(Baseline and Weeks 8, 16, 24 and 48.)
  • Visual Analog Scale (VAS) after the treatment.(Baseline)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验